Pfizer Venture Investments — Full Portfolio

Bolt Biotherapeutics is a clinical-stage biotech company developing novel immunotherapies that leverage innate immune system mechanisms to treat cancer.

BiotechHealthtechMedical DevicesSan Francisco, US

DEDr. Edgar G. Engleman(Founder)

Co-investorsPIPivotal Life SciencesRARA CapitalSASamsara BioCapitalSOSofinnova VenturesVIVivo CapitalNANan Fung Life Sciences+3 more

CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue.

BiotechHealthtechSouth San Francisco, US

SASean A. McCarthy(Chief Executive Officer and Chairman)inMarcia P. Belvin(SVP, Chief Scientific Officer)inDawn Benson(SVP, Quality and Product Manufacturing)inWCWayne Chu(Chief Medical Officer)RLRachael Lester(SVP, Chief Business Officer)inCOChris Ogden(Chief Financial Officer)in

Co-investorsATATEL VenturesCACanaan PartnersLOLongitude CapitalWEWellington ManagementOROrbiMedTHThird Rock Ventures

Enliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology.

BiotechHealthtechBoulder, US

Sam Kintz(Co-founder and Head of Pipeline)inJoe Lyssikatos(Co-founder and Research Fellow)Anish Patel(Co-founder and Chief Operating Officer)Rick Fair(Chief Executive Officer and Member of the Board of Directors)inHCHelen Collins(Chief Medical Officer)inBHBen Hohl(Chief Financial Officer and Head of Corporate Development)in

Co-investors5A5AM VenturesOROrbiMedRORoche Venture FundARARCH Venture PartnersBABay City CapitalJAJanus Henderson Investors+2 more

Ginkgo Bioworks builds autonomous labs that accelerate bioengineering for applications in pharmaceutical, agricultural, and industrial biotechnology.

AgTechAI & Machine LearningBiotechDeep TechHealthtechRoboticsBoston, US

JKJason Kelly(Founder)inRSReshma Shetty(Founder)inBCBarry Canton(Founder)inACAustin Che(Founder)inTKTom Knight(Founder)inBartholomew Canton(Executive Officer)

Co-investors1111.2 CapitalALAllen Institute for AI (AI2) IncubatorAZAzure Capital PartnersB3B3 HoldingBLBlue Owl CapitalCACannage Capital+62 more

Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion.

BiotechCambridge, US

JGJames G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)Richard Fair(President, Chief Executive Officer, Director)

BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)

Co-investorsBABay City CapitalNENew Enterprise Associates (NEA)RARA CapitalALAlexandriaARArix BioscienceJMJMI Equity+3 more

Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.

BiotechDeep TechHealthtech

NMNello Mainolfi(Founder)inBBBruce Booth(Chair)in

Co-investorsATAtlas VentureAVAvoro Capital AdvisorsBABain Capital Life SciencesBEBessemer Venture PartnersHAHatteras Venture PartnersMRMRL Ventures Fund+7 more

A Spanish-language blog that publishes articles on health and medicine topics, such as flu prevention and vaccination recommendations, for general readers.

BiotechMedia & EntertainmentAustin, US

Matthew Winkler(Director)Sinil Kim(Executive Officer)inPLPaul Lammers(Executive Officer, Director)inJon Irvin(Executive Officer)Casi DeYoung(Executive Officer)

BoardMichael Powell(Director)

Co-investorsNENew Enterprise Associates (NEA)COCorrelation VenturesOROrbiMedOUOUP (Osage University Partners)PFPfizer VenturesSOSofinnova Ventures

Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.

BiotechBeltsville, US

Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)inUGUdayan Guha(Executive Officer)inSteven P. Cobourn(Executive Officer)inSKSourav Kundu(Executive Officer)inKevin Shaw(Executive Officer)in

Co-investorsBABay City CapitalCACanaan PartnersLALAVLILilly Asia VenturesQUQuan CapitalSOSofinnova Ventures+4 more

Novocure develops Tumor Treating Fields therapy for treating aggressive forms of cancer.

BiotechHealthtechMedical Devices

Yoram PaltiinWFWilliam F. Doyle(Executive Chairman)FLFrank Leonard(Chief Executive Officer)in

Co-investorsWIWindham Capital Partners

Pyxis Oncology develops antibody-drug conjugates and immunotherapies targeting difficult-to-treat cancers to improve patient outcomes.

BiotechDigital HealthHealthtechMedical DevicesBoston, US

Thomas Civik(Interim Chief Executive Officer, Director)

BoardDSDavid Steinberg(Executive Officer, Director)inCWChristoph Westphal(Director)GVGeeta Vemuri(Director)inJak Knowles(Director)John Flavin(Director)

Co-investorsAGAgent CapitalLILifeSci Venture PartnersLOLongwood FundRARA CapitalTRTrans-Pacific Technology FundRTRTW Investments L.P.

Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.

BiotechDeep TechMedical DevicesCambridge, US

BCBharatt Chowrira(Executive Officer)inMSMichael Sheahan(Executive Officer)Jose Carlos Gutierrez-Ramos(Executive Officer, Director)inPMPaul Miller(Executive Officer)inABAoife Brennan(Executive Officer)inTSTodd Shegog(Executive Officer)in

Co-investorsATAtlas VentureCLCLI VenturesNENew Enterprise Associates (NEA)NSNSG VenturesSOSofinnova VenturesSOSolasta Ventures+1 more

RefleXion Medical develops SCINTIX autonomous radiotherapy, an external beam theranostic oncology platform that uses biological signals from radiopharmaceutical-labeled cancer cells to deliver real-time, motion-managed radiation to lung and bone tumors from primary or metastatic disease.

BiotechHealthtechMedical DevicesHayward, US

Samuel Mazin(Executive Officer, Director)inAkshay Nanduri(Executive Officer, Director)in

BoardJWJay Watkins(Director)in

Board seatRARana Al-Hallaq· per SEC Form D

Co-investorsASAscension VenturesCACatalio Capital Management, LPSOSofinnova PartnersSOSonder CapitalVEVenrock

Ablexis develops the AlivaMab Mouse, a transgenic mouse platform for antibody drug discovery used by major pharmaceutical companies.

BiotechDeep Tech

Larry(CEO and Founder)

Co-investorsCACalifornia Technology VenturesTHThird Rock Ventures

Adapsyn Bioscience is a biotech company focused on discovering and developing microbial natural product small molecules for therapeutic applications by leveraging genomic and chemical biology approaches.

AI & Machine LearningBiotechDeep TechHamilton, CA

Nathan Magarvey(Founder)

Co-investorsGEGenesys Capital

AMRA Medical is a global health informatics company specializing in MRI-based fat distribution and muscle composition analysis for precision medicine applications.

AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLinköping, SE

Magnus Borga(Co-Founder)inODOlof Dahlqvist Leinhard(Chief Executive Officer, Co-Founder)in

Co-investorsHEHealthCapINIndustrifonden

Anaveon develops engineered antibodies targeting immune system regulatory nodes to treat autoimmune diseases by selectively eliminating or reprogramming pathogenic immune cells.

BiotechBasel, CH

TThaminda(Chief Business Officer)inLPLaetitia Pouzol(Chief Scientific Officer)in

Co-investorsNONovartis Venture FundPOPontifax Venture CapitalFOForbion

Aquinnah Pharmaceuticals develops oral small-molecule therapeutics targeting pathologic biomolecular condensates, such as stress granules formed by RNA-binding proteins, to slow neurodegenerative diseases including ALS and Alzheimer's disease.

BiotechHealthtechLongevityCambridge, US

Benjamin Wolozin(CSO & Co-founder)inDr. Glenn Larsen(Co-founder, President and CEO)Dr. Ben Wolozin(Co-Founder and Chief Scientific Officer)

Co-investorsABAbbVie

Arkuda is an independent information platform that provides analysis and reviews of online gaming platforms operating in Azerbaijan, focusing on legal compliance, security protocols, and user protection for gaming platforms like Mostbet.

ConsumerGamingBaku, AZ

Co-investorsATAtlas VentureMIMission BiocapitalPFPfizer VenturesPIPivotal Life Sciences

Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.

AI & Machine LearningBiotechDeep TechHealthtechCambridge, US

MGMichael Gilman(Executive Officer, Director)inMDMark DeLong(CEO)inDNDavid Neafus(Executive Officer)inRussell C. Petter(Executive Officer)

BoardCCColleen Cuffaro(Director)inAEAlan E. Walts(Director)in

Co-investorsCACanaan PartnersPFPfizer VenturesADAdvent Life SciencesHBHBM Healthcare InvestmentsHBHBM PartnersNENextech Invest+2 more

Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.

BiotechHealthtechMedical Devices

Co-investorsANAndera PartnersDEDementia Discovery FundM M VenturesNONovartis Venture FundRARA CapitalSOSofinnova Partners+6 more

Autifony Therapeutics is a privately funded biopharmaceutical company developing treatments for neurological conditions including Fragile X Syndrome and orphan epilepsy syndromes.

BiotechHealthtechMedical DevicesStevenage, GB

Charles H. Large(Founder and Chief Executive Officer)inGiuseppe Alvaro(Director)Daniel UmbrichtBarbara Domayne-HaymanMartin GunthorpeHannah Selin

Co-investorsSVSV Health InvestorsDEDementia Discovery FundINInnovate UK

Autobahn Therapeutics develops orally administered small molecule prodrugs using a brain-targeting chemistry platform to create regenerative medicines for central nervous system (CNS) disorders.

BiotechDeep TechMedical DevicesSan Diego, US

KFKevin Finney(Chairman, President and CEO)inJBJohn Borkholder(Executive Officer)in

BoardKBKristina Burow(Director)inTCThomas Cahill(Director)Timothy Anderson(Director)Philip J DeSouza(Director)

Co-investorsARARCH Venture PartnersCACanaan PartnersMOMonograph Capital PartnersSASamsara BioCapitalINInsight PartnersNENewpath Partners

BD is a global medical technology company developing devices, systems, and solutions for medication administration, diagnostics, connected care, biopharmaceutical manufacturing, and interventional procedures.

Digital HealthHealthtechMedical DevicesFranklin Lakes, US

BioAtla develops novel monoclonal antibody and cell-based therapeutics for cancer treatment using proprietary platforms including Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!).

BiotechHealthtechMedical DevicesSan Diego, US

JMJay M. Short(Executive Officer, Director)RARichard A. Waldron(Executive Officer)inCarolyn Short(Director)

Co-investorsKEKeshif VenturesPAPappas CapitalHBHBM Healthcare InvestmentsPAPappas CapitalPFPfizer VenturesSOSoleus Capital

BioNTech is a biotechnology company developing immunotherapies that use the body's immune system, combining multiple therapeutic modalities and biological targets to treat cancer, infectious diseases, and other serious conditions.

BiotechHealthtechMainz, DE

OTOzlem Tureci(Executive Officer)USUgur Sahin(Executive Officer)inSPSierk Poetting(Executive Officer)inSMSean Marett(Executive Officer)inRRRyan Richardson(Executive Officer)inUŞUğur Şahin(Founder)in

Co-investorsHMHM Venture PartnersMAManta Ray VenturesMIMIG Capital AGONOnsight VenturesSASalviaANAndreessen Horowitz

BlueLight Therapeutics develops novel drug molecules using a proprietary structure-based discovery platform targeting high-value therapeutic targets in life sciences.

AI & Machine LearningBiotechDeep TechSouth San Francisco, US

Ariel G. Notcovich(Founder & CEO)Mark Gallop(CSO)Mira Chaurushiya(CBO)Anjanabha Saha(VP, Discovery)

Co-investors5A5AM VenturesPFPfizer Ventures

AbbVie is a biopharmaceutical company that discovers and delivers medicines for immune-mediated diseases and other therapeutic areas globally.

BiotechHealthtechMedical DevicesSan Diego, US

ABAdrian Bot(Executive Officer)LSLaura Shawver(Executive Officer, Director)inRFRamin Farzaneh-Far(Executive Officer)inJustin Thacker(Executive Officer)Karen Smith(Director)Fabio Pucci(Director)

Co-investorsFIFinchley Healthcare VenturesRARA CapitalSOSofinnova VenturesVIVida VenturesALAlexandriaFOForbion

Cartography develops antibody-based cancer therapies using single-cell sequencing and computational biology to identify precise cellular targets.

AI & Machine LearningBiotechDeep TechMedical DevicesSouth San Francisco, US

MMMax Mumbach(Founding Scientist, Target Discovery)inJVJeffrey Verboon(Founding Scientist, Computational Biology)inASAnsu Satpathy(Founder)KPKevin Parker, PhD(Chief Executive Officer, Board Director; co-founder)ASAnsuman Satpathy, MD, PhD(Co-founder; Board Director)HCHoward Chang(Founder)in

Co-investors8V8VCANAndreessen HorowitzARArtis VenturesCACatalio Capital Management, LPFIFinchley Healthcare VenturesGAGaingels+9 more

Developed targeted cancer therapies with companion diagnostics (Rubraca); IPO'd in 2011 (NASDAQ: CLVS).

Patrick Mahaffy(Founder)in

Co-investorsAIAisling CapitalFRFrazier Life SciencesNENew Enterprise Associates (NEA)RIRidgeback Capital

Casey Lynch(Founder)Kristen Gafric(Founder)Stephen Dominy(Founder)

Co-investorsDODolby Family VenturesSOSofinnova Partners

Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Alexander Nolte(Executive Officer)inDWDmitri Wiederschain(Executive Officer)in

BoardACAlexandra Cantley(Director)inSakae Asanuma(Director)inBMBriggs Morrison(Executive Officer, Director, Promoter)inIMIrena Melnikova(Director)in

Co-investorsLILifelinkMPMPM BioImpactBIBiotechnology Value FundMIMirae Asset Venture InvestmentPFPfizer VenturesPOPolaris Partners+1 more

Curve Therapeutics uses its mammalian cell-based Microcycle discovery platform to develop cyclic peptide and small molecule drugs against intracellular targets.

AI & Machine LearningBiotech

Co-investorsEPEpidarex CapitalCOColumbus Venture Partners

DEM BioPharma is a biotechnology company developing cancer therapies by targeting the immune system, drawing on genetic and immuno-oncology research.

BiotechHealthtechCambridge, US

NGNenad Grmusa(Chief Executive Officer)inJMJohn McCabe(Chief Financial and Operating Officer)in

Co-investorsALAlta PartnersASAstellas Venture Management LLCDCDC Investment PartnersLOLongwood FundUTUTokyo Innovation Platform Co. Ltd.INInsight Partners+1 more

eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company.

BiotechSolana Beach, US

Stephen F. Worland, Ph.D.(Executive Officer, Director)AMAlana McNulty(Executive Officer)in

BoardSimeon George(Director)JRJonathan Root(Director)inKen Haas(Director)Laurence Lasky(Director)

Co-investorsASAstellas Venture Management LLCMIMission Bay CapitalMIMission BiocapitalOUOUP (Osage University Partners)USUS Venture PartnersSOSofinnova Ventures

BiotechSanta Clara, US

Jeffrey Glenn(Director)David Cory(Executive Officer, Director)

BoardNKNina Kjellson(Director)inEd Engleman(Director)

Co-investorsCACanaan PartnersVIVivo CapitalVIVivo Ventures

Enara Bio discovers and validates Dark Antigens from non-coding genomic regions to identify novel cancer targets, and develops first-in-class bispecific T-cell engagers against these targets through its EnTiCE platform.

BiotechDeep TechMedical Devices

George Kassiotis(Co-founder)Drew Pardoll(Co-founder)HAHouman Ashrafian(Co-founder)inKevin Pojasekin

Co-investorsRARA CapitalSASamsara BioCapitalSVSV Health InvestorsPFPfizer VenturesDEDementia Discovery FundM M Ventures

Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.

BiotechDeep TechSan Diego, US

SDSergio Duron(Co-Founder & Chief Executive Officer)inSMSanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)in

BoardMMMarcos Milla(Director)inJLJay Lichter(Director)inTRTighe Reardon(Executive Officer)

Co-investorsFRFrazier Life SciencesLILightspeed Venture PartnersSASamsara BioCapitalAVAvalon BioVenturesPAPappas CapitalJ.J.P. Morgan Asset Management+1 more

Enodia Therapeutics develops small-molecule therapies that target protein degradation at the point of synthesis using a machine learning-enabled platform.

AI & Machine LearningBiotechDeep Tech

Yves Ribeill(CEO)

Co-investorsBPBpifranceELElaiaPFPfizer Ventures

Sam Holtzman(Founder)in

Co-investorsSOSofinnova VenturesBOBoulder Ventures

Medtronic designs and develops medical technology for treating complex diseases.

AI & Machine LearningDigital HealthHealthtechMedical Devices

Co-investors8V8VCCWCWRU Technology VenturesELElevate VenturesMEMenlo VenturesOAOak Investment PartnersQUQuesta Capital+5 more

EvolveImmune develops immunotherapy treatments for cancer patients.

BiotechHealthtechMedical DevicesBranford, US

Stephen Bloch(Co-founder and Chief Executive Officer)inDonmienne Leung(Manager)Ian Taylor(Manager)Jay Fine(President, Research and Development)

BoardDYDerek Yoon(Manager)inJasmina Marjanovic(Manager)in

Co-investorsSOSolasta VenturesPFPfizer VenturesELElm Street VenturesTATakeda Ventures

Flare Therapeutics develops small molecule medicines targeting transcription factors using a chemistry and proteomics platform that enables ligand discovery directly from cells.

AI & Machine LearningBiotechDeep TechHealthtech

JAJim Audia(Executive Vice President, Drug Discovery and Early Development, and Founding Scientist)JSJacob Stuckey(Senior Director, Biochemistry and Chemical Biology, and Founding Scientist)in

Co-investorsNENexTech VenturesPFPfizer VenturesTHThird Rock VenturesNENextech InvestSHShangBay Capital LLCAGAgent Capital

FoRx Therapeutics is a biotechnology company focused on oncology drug discovery and clinical development, targeting the DNA Damage Response (DDR) network with small molecule inhibitors.

BiotechDeep TechHealthtechBasel, CH

TBTarig Bashir(Chief Executive Officer (CEO))inJWJens Würthner(Chief Medical Officer (CMO))FZFrank Zenke(Chief Scientific Officer (CSO))in

Co-investorsM M VenturesNONovartis Venture FundOMOmega Funds

G-CON designs, manufactures, and installs prefabricated cleanroom systems for the biopharmaceutical, cell and gene therapy, and advanced therapy industries.

Advanced ManufacturingBiotechCleantechConstruction TechHardware

Robert Pedersen(Chief Executive Officer)

Co-investorsWPWP Global Partners

Genomic Health develops diagnostic tests and related services and runs health-equity initiatives aimed at improving access, awareness, and outcomes for patients and communities, including uninsured and underinsured populations.

BiotechDigital HealthHealthtechMedical Devices

SSSteve Shak(Founder)inKCKevin Conroy(CEO)inRandy Scott(Founder)

Co-investorsKLKleiner PerkinsVEVedanta Capital

Greywolf is a clinical-stage biotech developing antigen modulation therapies, including oral small molecules in Phase 1/2 trials, for people with cancers and autoimmune disorders.

BiotechDigital HealthHealthtechMedical DevicesOxford, GB

PJPeter Joyce(Co-founder)inTMTom McCarthy(Co-founder)in

Co-investorsANAndera PartnersCACanaan PartnersOXOxford Science EnterprisesBRBritish Patient CapitalEAEarlybird Venture CapitalPFPfizer Ventures

ImCheck Therapeutics develops next-generation immunotherapeutic antibodies targeting the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules for immune system modulation.

BiotechHealthtech

DODaniel Olive(Founder)

Co-investorsAGAgent CapitalANAndera PartnersKUKurma PartnersPUPureos BioventuresALAlexandriaBPBpifrance+4 more

Immunocodex develops lipid nanoparticle mRNA-based therapies targeting dendritic cells to induce immune tolerance for the treatment of autoimmune diseases.

AI & Machine LearningBiotechHealthtechLongevityMedical DevicesBoston, US

MCMark Carthy(Founder and CEO)FJFrancisco J. Quintana(Scientific Founder)

Immunos Therapeutics develops therapies for immuno-oncology and inflammatory diseases.

BiotechHealthtechMedical Devices

Co-investorsBABackbone VenturesBIBioMedPartnersGIGimvLILightspeed Venture PartnersMIMission BiocapitalPFPfizer Ventures+1 more

BiotechPhiladelphia, US

Philip R. Johnson, M.D.(Executive Officer, Director)inDora Mitchell(Executive Officer)LFLori Forrest(Executive Officer)Leon Moulder, Jr.(Director)BLBenjamin Lund(Director)in

BoardTomas Kiselak(Director)

Co-investorsAGAgent CapitalDCDC Investment PartnersLOLongwood FundOUOUP (Osage University Partners)QUQuan CapitalBABain Capital Life Sciences+3 more

Jnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins.

AI & Machine LearningBiotechDeep TechAustin, US

Joanne Dove Kotz(Founder)inJoel Barrish(Chief Scientific Officer)Donald W. Nicholson(Director)Matthew Hammond(Director)Caroline Stark Beer(Chief Business Officer)Carlo Rizzuto(Director)

Co-investorsAVAvalon BioVenturesBABain Capital Life SciencesRARA CapitalPFPfizer VenturesPOPolaris PartnersVEVersant Ventures

Kestrel Therapeutics develops targeted cancer therapies focused on inhibiting KRAS mutations across all tumor types using structure-based drug design.

BiotechDigital HealthHealthtechMedical DevicesBoston, US

Frank G. Haluska(Executive Officer, Director)in

BoardOmar Khalil(Director)Nicholas Saccomano(Director)Barbara Sosnowski(Director)Andrew Phillips(Director)Denis Patrick(Director)

Co-investorsSESection 32

BiotechSeattle, US

Shawn Iadonato(Executive Officer, Director)inRobert Hedequist(Executive Officer)Pauline Kenny(Executive Officer)inCharles Magness(Director)

Co-investorsKEKeiretsu ForumTSTSVCWEWellcome Trust

Levicept is a company in the life sciences sector with backing from prominent healthcare and pharmaceutical investors including Medicxi, Pfizer Ventures, Gilde Healthcare, and Advent Life Sciences.

BiotechHealthtechMedical Devices

Simon Westbrook(Founder and CSO)in

Co-investorsADAdvent Life SciencesGIGilde HealthcareINIndex VenturesMEMedicxiPFPfizer VenturesRERedwood Ventures

Following a 2025 merger of Mallinckrodt and Endo, the combined business separated into two companies: Keenova Therapeutics, which develops treatments for rare, stigmatized, or unaddressed conditions across areas such as immunology, urology, hepatology, ophthalmology, orthopedics, and critical care; and Par Health, which produces generics, sterile injectables, and active pharmaceutical ingredients backed by a U.S.-based manufacturing network.

Advanced ManufacturingBiotechHealthtechMedical Devices

Co-investorsARARCH Venture PartnersCRCross Creek AdvisorsSISignet Healthcare PartnersSOSofinnova Ventures

Mediartx develops novel therapies for patients with fibrotic diseases.

BiotechMedical DevicesBoston, US

Rahul Ballal, PhD(CEO)PYPaul Yaworsky, PhD(CSO)inRBRahul Ballal(Executive Officer, Director)inBrian Hubbard(Director)Stacey Brenner(Executive Officer)David de Graaf(Director)

Co-investorsAGAgent CapitalGIGimvLOLongwood FundMIMission BiocapitalNONovartis Venture FundONOno Venture Investment, Inc.+5 more

Day One (part of Servier) is a biopharmaceutical company developing targeted oncology medicines, with a focus on cancers affecting patients of all ages, including pediatric low-grade glioma (pLGG).

BiotechHealthtechCambridge, US

MICHAEL J. KAUFMAN(Executive Officer)inDonald Bergstrom(Executive Officer)inAPANNA PROTOPAPAS(Executive Officer, Director)TLTimothy Lowinger(Executive Officer)Eva Jack(Executive Officer)Wayne Foster(Executive Officer)

Co-investorsBABain Capital Life SciencesF-F-Prime CapitalLILightstone VenturesNENew Enterprise Associates (NEA)NENextech InvestRHRho Ventures+3 more

Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications.

BiotechMedical DevicesUtrecht, NL

TLTon Logtenberg(Executive Officer, Director)inMTMark Throsby(Executive Officer)inHLHui Liu(Executive Officer)inJCJohn Crowley(Executive Officer)inLAL. Andres Sirulnik(Executive Officer)inLBLex Bakker(Executive Officer)in

Co-investorsAVAvoro Capital AdvisorsRARA CapitalSOSofinnova Ventures

MindImmune develops therapeutics targeting the immune drivers of neurodegenerative diseases such as Alzheimer's, focusing on immune cells that respond to amyloid plaques before they enter the brain.

BiotechHealthtechKingston, US

Robert B. Nelson(Executive Officer, Director)Frank S. Menniti(Executive Officer, Director)inStevin Zorn(Executive Officer, Director)inISIsaac Stoner(CEO)in

BoardRichard G. Horan(Director)RBReetika Bhardwaj(Director)in

Co-investorsDODolby Family VenturesSLSlater Technology FundARARCH Venture PartnersPFPfizer Ventures

Mission Therapeutics develops therapeutics targeting deubiquitylating enzymes (DUBs), such as USP30, which regulate ubiquitylation and processes including mitophagy and protein homeostasis.

BiotechHealthtech

Co-investorsRORoche Venture FundRORosetta Capital Ltd.SOSofinnova PartnersSRSR One Capital ManagementIPIP Group

Targeting mitochondria for neurodegenerative disease therapies.

BiotechNew York, US

NHNicholas Hertz(Director)Doug Crawford(Director)Daniel de Roulet, Jr.(Executive Officer, Director)

BoardJohannes Fruehauf(Director)

Co-investorsMIMission Bay CapitalMIMission Biocapital

Montis Biosciences develops anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome and a second CD93 program in lung squamous cell carcinoma.

BiotechHealthtechLeuven, BE

FGFederico Grossi(Clinical Advisor & Acting CMO)

Co-investorsDRDroia VenturesPFPfizer VenturesVIVIBPOPolaris Partners

Montis Biosciences is a biotechnology company developing anti-C1q antibodies that target both the complement and myeloid axes to treat neuroinflammatory, autoimmune, neurodegenerative and ophthalmic diseases, with a lead program in Guillain-Barré syndrome.

BiotechHealthtechLeuven, BE

Federico Grossi(Clinical Advisor & Acting CMO)

Co-investorsDRDroia VenturesPFPfizer VenturesVIVIB

Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.

BiotechMedical Devices

MDMark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)CKCalvin Kuo(Scientific Co-Founder)KFKatie Fanning(President & Chief Executive Officer)in

Co-investorsARARCH Venture PartnersJDJDRF T1D FundMRMRL Ventures FundONOno Venture Investment, Inc.SOSofinnova PartnersABAbbVie+6 more

NexImmune is a biotechnology company developing antigen-directed immunotherapies based on its proprietary AIM nanoparticle platform, which mimics dendritic cell signaling to activate antigen-specific T cell responses.

BiotechMedical DevicesGaithersburg, US

Jonathan Schneck(Director)Alain Cappeluti(Executive Officer, Director)Kenneth Carter(Executive Officer, Director)

BoardJanis Naeve(Director)James Barrett(Director)

Co-investorsRARapha Capital Management, LLCNENew Enterprise Associates (NEA)

Nimbus Therapeutics is a biotechnology company that designs precision small molecule medicines using a computational, multidisciplinary drug discovery approach.

AI & Machine LearningBiotechDeep TechHealthtech

Co-investorsACAccess BiotechnologyATAtlas VentureBABain Capital Life SciencesDEDementia Discovery FundGVGV (Google Ventures)LILightstone Ventures+4 more

Normunity develops biologic anti-cancer therapies that act at the interface of the immune system and tumors, targeting mechanisms tumors use to evade immune surveillance.

BiotechHealthtech

RHRachel Humphrey(Founding Chief Executive Officer)inLieping Chen(Scientific Founder)MKMitchell Keegan(Chief Development Officer)inWLWilliam LaRochelle(Chief Scientific Officer)inSMStacy M. Plum(Chief Technology Officer)

Co-investorsSASanofi VenturesTATaiho Ventures, LLCPFPfizer VenturesSASamsara BioCapitalCACanaan PartnersCOConnecticut Innovations+6 more

Quince Therapeutics is a clinical-stage biopharmaceutical company developing eDSP, an investigational therapy studied in a Phase 3 clinical trial (NEAT) for patients with Ataxia-Telangiectasia (A-T).

BiotechHealthtechWest Lafayette, US

Philip S. Low, Ph.D.(Executive Officer, Director)David Lamond(Director)Daniel Hasler(Director)Dirk Thye, M.D.(Executive Officer, Director)William J. Rutter(Director)Alex Andrianopoulos(Director)

Co-investorsBRBreakout VenturesELElevate Ventures

Nucleome develops 3D genomics technology to map genetic variants in the non-coding genome to the genes they dysregulate, with applications in understanding inflammatory diseases and discovering therapeutic targets.

AI & Machine LearningBiotechDeep Tech

Co-investorsM M VenturesOXOxford Science EnterprisesBRBritish Patient CapitalJJJJDCPFPfizer Ventures

Palleon Pharma develops small molecule and biologic drugs targeting autoimmune and inflammatory diseases using proprietary glycoscience platforms.

BiotechDigital HealthMedical DevicesWaltham, US

Jim Broderick(Co-Founder)inJohn Hennessy(Executive Officer)Karen Hong(Director)James Lee(Director)Stephen Hoffman(Director)Li Peng(Chief Scientific Officer)

Co-investorsMAMatrix Capital ManagementPFPfizer VenturesSRSR One Capital ManagementBIBioHealth Innovation, Inc.TATakeda VenturesVEVertex Ventures HC

PrescriberPoint operates an AI-enabled medication access platform that helps clinicians get patients onto prescribed therapies by providing prescribing support, coverage and cost-savings lookups in one place.

AI & Machine LearningDigital HealthHealthtechSaaS

BiotechCambridge, US

Robert Prentiss(Executive Officer)Ronald C. Renaud, Jr.(Executive Officer, Director)Thomas McCauley(Executive Officer)

BoardBrian Gallagher(Director)JFJean- Francois Formela(Director)inJoshua Resnick(Director)

Co-investorsATAtlas Venture

ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.

AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US

Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)

Co-investorsAJAju IB InvestmentECEcoR1 CapitalEVEvolution VC PartnersMPMPM BioImpactOROrbiMedOUOUP (Osage University Partners)+6 more

Resilience is a contract development and manufacturing organization (CDMO) that manufactures complex pharmaceutical products and active pharmaceutical ingredients to broaden access to medicines and protect biopharmaceutical supply chains against disruption.

Advanced ManufacturingBiotechEnterprise SoftwareBlue Ash, US

William S. Marth(Chief Executive Officer)William S. Marth, RPh., MBA(President & CEO)

BoardRNRobert Nelsen(Chairman, Resilience; Founder, ARCH)

Co-investors8V8VCARARCH Venture PartnersCACatalio Capital Management, LPGLGlobal Health Investment CorporationGVGV (Google Ventures)KOKoch Disruptive Technologies+14 more

Rhythm Therapeutics develops precision medicines for rare neuroendocrine diseases, particularly those affecting the melanocortin-4 receptor pathway.

BiotechDigital HealthHealthtechMedical DevicesBoston, US

Keith Gottesdiener(Executive Officer, Director)inBHBart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)inDMDavid Meeker(President and Chief Executive Officer)in

BoardETEdward T. Mathers(Director)inJSJonathan Silverstein(Director)inNENeil Exter(Director)in

Co-investorsFOForesite CapitalHEHEALTHCARE ROYALTY PARTNERSNENew Enterprise Associates (NEA)WEWellington ManagementOROrbiMedTHThird Rock Ventures

Saama provides AI-based data analytics solutions and services for the life sciences industry, with a focus on accelerating clinical trials.

AI & Machine LearningData & InfrastructureDigital HealthHealthtechSaaSCampbell, US

SKSuresh Katta(Executive Officer, Director)inSHSimon Ho(Executive Officer)in

BoardMMMarc McMorris(Director)inKen Coleman(Director)Dan Fishback(Director)William Binch(Director)

Co-investorsCACarrick Capital PartnersINIntermountain HealthMCMcKesson VenturesMEMerck Global Health Innovation FundMSMSD Global Health Innovation Fund

Simcha is a biotechnology company developing new cancer medicines based on immune biology research.

BiotechHealthtechNew Haven, US

ARAaron Ring(Executive Officer, Director)inBMBeatrice McQueen(Chief Operating Officer)inSRSanuj Ravindran(Chief Executive Officer)Jeremy Barton(Chief Medical Director)HUHirdesh Uppal(Senior Vice President Translational Research and Development Sciences)Joseph Catino(Executive Officer)

Co-investorsCOConnecticut InnovationsSRSR One Capital ManagementAXAxial VCBIBiotechnology Value FundRORock Springs CapitalSASamsara BioCapital

SpringWorks is a biotechnology company focused on developing innovative treatments for cancer patients.

BiotechDigital HealthHealthtechMedical DevicesAustin, US

Co-investorsFRFrazier Life Sciences

Qiagen manufactures enzymes and molecular biology products, plus scientific research tools and software for studying biological targets and pathways.

BiotechData & InfrastructureDigital HealthHealthtechMedical Devices

Co-investorsHAHarmonic Growth PartnersYSYsios Capital

STORM Therapeutics is a clinical-stage biotechnology company developing small molecule drugs that target RNA modifying enzymes to reprogram cells through RNA biology.

BiotechHealthtechMedical Devices

Co-investorsCACambridge Innovation CapitalFAFast Track InitiativeM M VenturesSESeroba Life SciencesTATaiho Ventures, LLCUTUTokyo Innovation Platform Co. Ltd.+3 more

Strata Oncology develops precision oncology biomarkers and predictive diagnostic tools for cancer treatment, including treatment response scores for antibody-drug conjugates (ADCs) and an Immunotherapy Response Score for anti-PD-1/PD-L1 therapies.

AI & Machine LearningBiotechDigital HealthMedical DevicesAnn Arbor, US

Daniel Rhodes(Executive Officer, Director)Dan Rhodes(Founder)inScott Tomlins(Founder)inMatthew Martin(Executive Officer)Jeffrey Williams(Executive Officer, Director)

BoardCOChristopher O'Donnell(Director)in

Co-investorsARArboretum VenturesBABaird CapitalMEMerck Global Health Innovation FundMSMSD Global Health Innovation FundWEWellington ManagementDEDeerfield Management Company+1 more

TRexBio develops biologic medicines targeting inflammation in autoimmune and inflammatory diseases by decoding human tissue biology.

AI & Machine LearningBiotechDeep TechHealthtech

Johnston Erwin(Chief Executive Officer)Ali Zarrin(Chief Scientific Officer)

Co-investorsAVAvego BioScience CapitalDEDelos CapitalDEDementia Discovery FundSVSV Health InvestorsAGAgent CapitalPOPolaris Partners

TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.

BiotechDeep TechHealthtechLexington, US

PTPatrick Trojer(President & Chief Executive Officer)in

Co-investorsASAscenta CapitalATAtlas VentureLILightspeed Venture PartnersRARA CapitalBEBessemer Venture PartnersPFPfizer Ventures+3 more

TRIMTech Therapeutics is a biotechnology company focused on drug discovery and development, backed by investors including Cambridge Innovation Capital and BGF.

BiotechDeep TechLongevityMedical DevicesCambridge, GB

Damian Crowther, PhD FRCP(Co-founder, Head of Research)Dr. Leo James(Co-founder, Group Leader at MRC Laboratory of Molecular Biology)Dr. William McEwan(Co-founder, Group Leader at UK Dementia Research Institute, University of Cambridge)Nicki Thompson, PhD(CEO)Nicki Thompson(CEO)

Co-investorsCACambridge Innovation CapitalPFPfizer VenturesSVSV Health InvestorsM M VenturesSTStart CodonDIDiamond Edge Ventures

Vibrant Therapeutics develops multispecific antibody-based prodrugs with conditional activation and targeted delivery for patients with oncological, autoimmune, and neurological diseases.

AI & Machine LearningBiotechHealthtech

Co-investorsPFPfizer Ventures

UWIN33 is an online casino and slot-game platform offering slots, live casino, sports betting, and arcade games in the Thai-language market.

ConsumerGaming

RefleXion Medical develops autonomous radiotherapy technology that uses biological signals from cancer cells to detect and treat solid tumors in the lung or bone.

BiotechHealthtechMedical DevicesHayward, US

Akshay Nanduri(Founder)Samuel Mazin(Founder)

Co-investorsSOSofinnova PartnersVEVenrock

Ironwood Pharmaceuticals is a gastrointestinal healthcare company developing treatments for GI diseases.

BiotechHealthtech

VitaDAO is a decentralized autonomous organization that funds and coordinates longevity and aging research using AI agents, decentralized governance, and on-chain funding mechanisms such as IP-NFTs.

BiotechCrypto & Web3Longevity

Co-investorsCOCollab+CurrencySOSora VenturesTITioga Capital Partners

Vivet Therapeutics is a clinical-stage biotechnology company developing recombinant adeno-associated virus (rAAV) gene therapies for rare, inherited metabolic diseases, including Wilson's Disease and cerebrotendinous xanthomatosis.

BiotechHealthtechParis, FR

Co-investorsHEHealthCapKUKurma PartnersNONovartis Venture FundRORoche Venture FundYSYsios CapitalCOColumbus Venture Partners+1 more

WEX Health provides benefits administration technology and services, including enrollment, ACA and COBRA compliance, and reimbursement and savings accounts such as HSAs, FSAs, and HRAs.

FintechHR TechSaaS

Neurodegenerative disease drug discovery correcting misfolded-protein cellular pathologies.

ConsumerHealthtechMedia & EntertainmentBoston, US

N. Anthony Coles(Executive Officer, Director)RPRichard Peters(Executive Officer, Director)Paulash Mohsen(Executive Officer)Brigitte Robertson(Executive Officer)RARichard A. Heyman(Director)inJeffery W. Kelly(Director)

Co-investorsALAltium CapitalDODolby Family VenturesSASanofi VenturesALAlexandriaFIFidelity InvestmentsREREDMILE